Innovation Pharmaceuticals Inc (IPIX)

[lousy engineer]

Good cancer drugs are scarce and valuable commodities, and potential Big Pharma partners and institutional investors are forever scouting for opportunities to buy, license or invest in companies with drugs that have a high probability of success. Said another way, there are very few, if any, cancer drugs that come out of nowhere to be big sellers.

Therefore, market value can be a reasonably accurate proxy for the future success of a cancer drug in a phase III clinical trial. Consider Pharmacyclics (PCYC) and its blood cancer drug ibrutinib. The company's nearly $5 billion market value and a partnership with Johnson & Johnson (JNJ) screams investor confidence in the outcome of ongoing phase III studies.- AF

If Kevetrin has a blockbuster potential, big pharmas are going to fight to get it .